NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny’s guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care.
Progyny’s global benefits solution supports multinational employers and their employee populations in over 100 countries. Progyny’s services allow employers the flexibility to offer fertility and family building benefits that comply with the intricacies of country-specific laws and regulations as it relates to fertility and family building services, treatments, and benefit design.
“Employers recognize the importance of providing fertility and family building benefits and want to be able to streamline these efforts to ensure their employees have equitable benefits and consistent high-touch experiences, regardless of where they live,” said Pete Anevski, CEO of Progyny. “We’re excited to broaden our support on a global scale.”
Progyny’s enhanced global services include:
Jenny Saft, co-founder of Apryl, said, “We saw the incredible solution and impact Progyny had created in the U.S. and founded Apryl with the vision of achieving this success globally. The Apryl team is thrilled to join Progyny to bring employers and their employees around the world access to best-in-class benefits that make dreams of family come true.”
For more information about Progyny visit www.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a transformative fertility, family building and women’s health benefits solution, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Selena Yang
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$14.41 |
Daily Change: | 0.43 3.08 |
Daily Volume: | 102,550 |
Market Cap: | US$1.300B |
November 14, 2024 November 12, 2024 August 06, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB